Venetoclax

Detection of ctDNA in patients with MCL and CLL 5:56
Detection of ctDNA in patients with MCL and CLL
Constantine Tam
Waldenstrom’s macroglobulinemia in the era of immunotherapy 4:43
Waldenstrom’s macroglobulinemia in the era of immunotherapy
Morie Gertz
Highlights in leukemia research: MRD as a prognostic factor 3:24
Highlights in leukemia research: MRD as a prognostic factor
Arnon Nagler
Major breakthroughs in BPDCN treatment 2:09
Major breakthroughs in BPDCN treatment
Naveen Pemmaraju
Clinical trials investigating tagraxofusp in BPDCN and beyond 1:53
Clinical trials investigating tagraxofusp in BPDCN and beyond
Naveen Pemmaraju
Treating AML with BCL-2 inhibitors 1:49
Treating AML with BCL-2 inhibitors
Thomas Prebet
The future of immunotherapies for multiple myeloma 4:38
The future of immunotherapies for multiple myeloma
Luciano Costa
The next five years of multiple myeloma treatment 1:39
The next five years of multiple myeloma treatment
Graham Jackson
Treating relapsed/refractory CLL with venetoclax 1:46
Treating relapsed/refractory CLL with venetoclax
Barbara Eichhorst
Genomic aberrations in CLL 3:14
Genomic aberrations in CLL
Richard Rosenquist
The need for new treatment regimens in older AML patients 3:04
The need for new treatment regimens in older AML patients
Farhad Ravandi
Management of AL amyloidosis: measurement modalities, transplantation & CAR-T 4:04
Management of AL amyloidosis: measurement modalities, transplantation & CAR-T
Morie Gertz
Allo-HSCT and novel drugs for refractory AML 2:26
Allo-HSCT and novel drugs for refractory AML
Mohamad Mohty
COVID-19 in the GAIA/CLL13 trial 1:54
COVID-19 in the GAIA/CLL13 trial
Barbara Eichhorst
Treatment approaches for mutated and unmutated CLL 2:20
Treatment approaches for mutated and unmutated CLL
Freda Stevenson
Impact of COVID-19 on CLL treatment in Italy 2:21
Impact of COVID-19 on CLL treatment in Italy
Antonio Cuneo
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals